Skip to main content

Table 3 Performance of AKI markers for predicting persistent AKI

From: Urine cell cycle arrest biomarkers distinguish poorly between transient and persistent AKI in early septic shock: a prospective, multicenter study

Parameters Sample (n) AUROC [95% CI] Cutoff value Younden index Sensitivity [95% CI] Specificity [95% CI] PPV [95% CI] NPV [95% CI] Brier score#
[TIMP-2]*[IGFBP7] at 0 h ([ng/ml]2/1000) 184 0.67 [0.59–0.73] > 1.03 0.33 74 [63–83] 59 [48–68] 59 [53–66] 73 [65–80] 0.23
[TIMP-2]*[IGFBP7] at 6 h ([ng/ml]2/1000) 172 0.73 [0.66–0.80] > 2.3 0.36 48 [36–60] 88 [79–93] 75 [63–84] 68 [63–73] 0.21
[TIMP-2]*[IGFBP7] at 12 h ([ng/ml]2/1000) 165 0.70 [0.63–0.77] > 1.1 0.39 56 [44–68] 83 [74–90] 71 [60–80] 72 [65–77] 0.21
[TIMP-2]*[IGFBP7] at 24 h ([ng/ml]2/1000) 156 0.68 [0.60–0.75] > 0.43 0.27 67 [54–78] 60 [49–70] 54 [46–61] 72 [64–79] 0.21
∆[TIMP-2]*[IGFBP7] 0 to 6 h (%) 172 0.59 [0.51–0.67] > − 55.6 0.22 78 [67–87] 44 [34–54] 51 [42–61] 72 [59–83] 0.24
∆[TIMP-2]*[IGFBP7] 0 to 12 h (%) 165 0.57 [0.49–0.65] > − 67.1 0.16 74 [62–84] 42 [32–53] 49 [39–58] 68 [55–80] 0.24
Baseline urine output (ml/kg/h) 184 0.78 [0.71–0.83] < 0.40 0.50 62 [51–72] 88 [80–94] 81 [71–88] 73 [67–78] 0.21
Urine output 6 to 12 h (ml/kg/h) 184 0.74 [0.67–0.80] < 0.46 0.46 58 [47–69] 88 [80–93] 80 [69–87] 72 [66–77] 0.21
Urine output 12 to 24 h (ml/kg/h) 184 0.75 [0.68–.081] < 0.47 0.42 54 [43–65] 88 [80–94] 79 [66–70] 61 [61–78] 0.22
SCr concentration at baseline (μmol/l) 184 0.63 [0.56–0.70] > 179 0.29 52 [41–63] 77 [67–85] 66 [53–77] 65 [56–74] 0.24
SCr concentration at 24 h* (μmol/l) 160 0.84 [0.77–0.89] > 139 0.60 79 [67–88] 81 [71–88] 75 [63–84] 84 [75–91] 0.16
Kinetic eGFR* (ml/min per 1.73 m2) 160 0.86 [0.80–0.91] < 51 0.59 79 [67–88] 80 [71–88] 74 [63–84] 84 [75–91] 0.15
  1. AUROC area under the receiver-operating characteristic curve, TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7, SCr serum creatinine, eGFR estimated glomerular filtration rate, PPV positive predictive value, NPV negative predictive value
  2. *Excluding patients undergoing renal replacement therapy at 24 h
  3. #The maximum value expected is 0.25 given the prevalence of persistent AKI in the cohort (46%)